[go: up one dir, main page]

AR088044A1 - Proteinas de fusion para tratar trastornos metabolicos - Google Patents

Proteinas de fusion para tratar trastornos metabolicos

Info

Publication number
AR088044A1
AR088044A1 ARP120103553A AR088044A1 AR 088044 A1 AR088044 A1 AR 088044A1 AR P120103553 A ARP120103553 A AR P120103553A AR 088044 A1 AR088044 A1 AR 088044A1
Authority
AR
Argentina
Prior art keywords
fusion proteins
metabolic disorders
treat metabolic
fgf21
disorders
Prior art date
Application number
Other languages
English (en)
Inventor
Licht Stuart
Hamamatsu Norio
L Caplan Shari
S Daniels Douglas
R Boettcher Brian
Craig Weldon Stephen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR088044A1 publication Critical patent/AR088044A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a la identificación de proteínas de fusión que comprenden variantes polipeptídicas y proteicos del factor de crecimiento de fibroblastos 21 (FGF21) que tienen propiedades farmacéuticas mejoradas. También se describen métodos para el tratamiento de trastornos asociados con el FGF21, incluyendo trastornos metabólicos. Reivindicación 1: Una proteína de fusión que comprende una variante del FG21 y una región Fc.
ARP120103553 2011-09-26 2012-09-26 Proteinas de fusion para tratar trastornos metabolicos AR088044A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161539280P 2011-09-26 2011-09-26

Publications (1)

Publication Number Publication Date
AR088044A1 true AR088044A1 (es) 2014-05-07

Family

ID=46970456

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP120103553 AR088044A1 (es) 2011-09-26 2012-09-26 Proteinas de fusion para tratar trastornos metabolicos
ARP210102949A AR123908A2 (es) 2011-09-26 2021-10-25 Proteínas de fusión para tratar trastorno metabólicos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP210102949A AR123908A2 (es) 2011-09-26 2021-10-25 Proteínas de fusión para tratar trastorno metabólicos

Country Status (41)

Country Link
US (6) US9006400B2 (es)
EP (2) EP3321276B1 (es)
JP (4) JP6186361B2 (es)
KR (1) KR102085605B1 (es)
CN (2) CN107266579B (es)
AP (1) AP2014007543A0 (es)
AR (2) AR088044A1 (es)
AU (1) AU2012316052A1 (es)
BR (1) BR112014007069B1 (es)
CA (1) CA2849464C (es)
CL (2) CL2014000736A1 (es)
CO (1) CO6920257A2 (es)
CR (1) CR20140140A (es)
CU (2) CU24314B1 (es)
CY (2) CY1120928T1 (es)
DK (2) DK3321276T3 (es)
EA (1) EA039633B1 (es)
ES (2) ES2895080T3 (es)
GT (1) GT201400055A (es)
HR (2) HRP20181558T1 (es)
HU (2) HUE039857T2 (es)
IL (1) IL231533B (es)
IN (1) IN2014DN02043A (es)
JO (1) JO3476B1 (es)
LT (2) LT3321276T (es)
MA (1) MA35437B1 (es)
MX (1) MX350273B (es)
MY (1) MY166059A (es)
PE (2) PE20141551A1 (es)
PL (2) PL2760475T3 (es)
PT (2) PT2760475T (es)
RS (2) RS57868B1 (es)
SG (2) SG10201602339XA (es)
SI (2) SI2760475T1 (es)
SM (1) SMT202100595T1 (es)
TN (1) TN2014000109A1 (es)
TW (1) TWI593708B (es)
UA (1) UA113856C2 (es)
UY (2) UY34346A (es)
WO (1) WO2013049247A1 (es)
ZA (1) ZA201401700B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5419689B2 (ja) 2006-07-25 2014-02-19 リポクセン テクノロジーズ リミテッド 顆粒球コロニー刺激因子の誘導体化
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3590949B1 (en) 2010-10-01 2022-05-18 ModernaTX, Inc. Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP4306165A3 (en) 2011-07-01 2024-04-17 NGM Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
JO3476B1 (ar) 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
JP2015513912A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． タンパク質の産生のための修飾ポリヌクレオチド
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2828505T3 (es) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
US9925242B2 (en) 2012-12-27 2018-03-27 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CN105980401A (zh) 2013-10-03 2016-09-28 现代治疗公司 编码低密度脂蛋白受体的多核苷酸
WO2015057908A1 (en) 2013-10-18 2015-04-23 Novartis Ag Methods of treating diabetes and related disorders
MX377380B (es) 2013-10-28 2025-03-10 Ngm Biopharmaceuticals Inc Modelos de cáncer y métodos asociados.
US9738716B2 (en) 2014-01-24 2017-08-22 Ngm Biopharmaceuticals, Inc. Beta klotho binding proteins and methods of use thereof
JP6712230B2 (ja) * 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
RU2729161C2 (ru) * 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
LT3412302T (lt) 2014-10-24 2021-07-26 Bristol-Myers Squibb Company Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
RU2752530C2 (ru) 2015-08-03 2021-07-29 Новартис Аг Способы лечения расстройств, связанных с fgf21
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
EP3888672A1 (en) 2015-11-09 2021-10-06 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
MX2018014256A (es) * 2016-05-20 2019-08-16 Harvard College Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
EP3463427A4 (en) 2016-05-25 2020-03-11 Board of Regents, The University of Texas System METHOD AND COMPOSITIONS FOR TREATING SECRETORIC DISEASES
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN107759694B (zh) * 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CA3047862A1 (en) 2016-12-22 2018-06-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
ES3014984T3 (en) * 2017-03-14 2025-04-28 Sunshine Lake Pharma Co Ltd Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CN107050429B (zh) * 2017-04-01 2020-12-15 杭州生物医药创新研究中心 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用
MX2019013210A (es) * 2017-05-05 2020-07-20 Trefoil Therapeutics Inc Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos.
CN109836504B (zh) * 2017-11-24 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
WO2019119673A1 (zh) 2017-12-19 2019-06-27 北京吉源生物科技有限公司 一种双基因修饰的干细胞及其用途
CN119386161A (zh) 2017-12-22 2025-02-07 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
JP7475276B2 (ja) 2018-02-08 2024-04-26 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Ｆｇｆ２１バリアント、融合タンパク質及びそれらの適用
WO2019243557A1 (en) * 2018-06-21 2019-12-26 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
MX2021000016A (es) 2018-07-03 2021-03-09 Bristol Myers Squibb Co Formulaciones de factor de crecimiento de fibroblastos (fgf-21).
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
CN111944055B (zh) 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
CN112386575B (zh) * 2019-08-19 2023-03-21 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干制剂
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
IL293894A (en) 2019-12-20 2022-08-01 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
JP6924291B2 (ja) 2020-01-21 2021-08-25 シャープ株式会社 端末装置、方法、および、集積回路
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
CA3184546A1 (en) * 2020-07-02 2022-01-06 Sanofi Glp-1r agonist / fgf21 fusion proteins
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
CN113265007B (zh) * 2021-06-10 2022-02-15 江南大学 一种治疗代谢疾病的融合蛋白及其制备方法和应用
CN115286705B (zh) * 2021-12-30 2024-05-10 长江大学 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用
WO2023245543A1 (en) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Uses of fgf21 fusion proteins
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2025108432A1 (en) * 2023-11-23 2025-05-30 Therorna Shanghai Co., Ltd. Circular rna encoding fgf21 and the use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
EP0315456B1 (en) 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU1922101A (en) 1999-11-18 2001-05-30 Chiron Corporation Human fgf-21 gene and gene expression products
JP2003535037A (ja) 1999-12-23 2003-11-25 ザイモジェネティクス，インコーポレイティド 炎症を治療する方法
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
AU2004303783A1 (en) * 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
ATE444306T1 (de) * 2004-05-13 2009-10-15 Lilly Co Eli Fgf-21-fusionsproteine
BRPI0514790A (pt) * 2004-09-02 2008-06-24 Lilly Co Eli muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
JP2008528487A (ja) 2005-01-21 2008-07-31 イーライ リリー アンド カンパニー 心臓血管疾患を治療する方法
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
AU2009308163B2 (en) 2008-10-24 2013-01-10 Novartis Ag Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
TWI436776B (zh) * 2009-05-05 2014-05-11 Amgen Inc Ｆｇｆ２１突變體及其用途
WO2010148142A1 (en) * 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
JP2013514795A (ja) 2009-12-22 2013-05-02 ノバルティス アーゲー 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質
DE102010038140B4 (de) * 2010-10-13 2020-06-18 Hettich-Heinze Gmbh & Co. Kg Beschlag für eine Schiebetür
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
JO3476B1 (ar) * 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
JP6712230B2 (ja) 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
LT3412302T (lt) 2014-10-24 2021-07-26 Bristol-Myers Squibb Company Modifikuoti fgf-21 polipeptidai ir jų panaudojimai

Also Published As

Publication number Publication date
CY1124697T1 (el) 2022-07-22
EP3321276A2 (en) 2018-05-16
DK2760475T3 (en) 2018-10-15
WO2013049247A1 (en) 2013-04-04
PL2760475T3 (pl) 2018-11-30
ES2895080T3 (es) 2022-02-17
TWI593708B (zh) 2017-08-01
CR20140140A (es) 2014-07-15
IL231533B (en) 2018-06-28
MY166059A (en) 2018-05-22
SG11201400538QA (en) 2014-06-27
TW201326213A (zh) 2013-07-01
JP6186361B2 (ja) 2017-08-23
JP2020007314A (ja) 2020-01-16
CO6920257A2 (es) 2014-04-10
LT3321276T (lt) 2021-11-10
KR102085605B1 (ko) 2020-03-06
CN103945871A (zh) 2014-07-23
BR112014007069A2 (pt) 2017-03-28
NZ622998A (en) 2016-07-29
ZA201401700B (en) 2015-01-28
SG10201602339XA (en) 2016-05-30
CU20140034A7 (es) 2014-08-28
CN107266579B (zh) 2022-07-12
EP3321276B1 (en) 2021-07-28
IN2014DN02043A (es) 2015-05-15
HUE055584T2 (hu) 2021-12-28
SMT202100595T1 (it) 2022-01-10
US20150166622A1 (en) 2015-06-18
EP2760475B1 (en) 2018-07-04
AU2012316052A1 (en) 2014-04-17
CL2016002215A1 (es) 2016-10-28
US20130079500A1 (en) 2013-03-28
US20160193297A1 (en) 2016-07-07
RS57868B1 (sr) 2018-12-31
CL2014000736A1 (es) 2014-10-03
PT3321276T (pt) 2021-10-27
EA039633B1 (ru) 2022-02-18
KR20140069250A (ko) 2014-06-09
IL231533A0 (en) 2014-04-30
US9006400B2 (en) 2015-04-14
JO3476B1 (ar) 2020-07-05
US20240261372A1 (en) 2024-08-08
US20180369332A1 (en) 2018-12-27
HUE039857T2 (hu) 2019-02-28
JP2014534172A (ja) 2014-12-18
MX350273B (es) 2017-08-31
JP7339372B2 (ja) 2023-09-05
PE20141551A1 (es) 2014-10-26
US12527841B2 (en) 2026-01-20
JP2022058546A (ja) 2022-04-12
US11944664B2 (en) 2024-04-02
TN2014000109A1 (en) 2015-07-01
SI2760475T1 (sl) 2018-10-30
US20210386824A1 (en) 2021-12-16
CU20150171A7 (es) 2016-07-29
US10076554B2 (en) 2018-09-18
CU24206B1 (es) 2016-10-28
JP6567613B2 (ja) 2019-08-28
BR112014007069B1 (pt) 2020-12-15
CU24314B1 (es) 2018-02-08
CA2849464A1 (en) 2013-04-04
UA113856C2 (xx) 2017-03-27
SI3321276T1 (sl) 2021-11-30
AR123908A2 (es) 2023-01-25
CA2849464C (en) 2024-01-30
US11129874B2 (en) 2021-09-28
MX2014003677A (es) 2014-04-30
PE20181159A1 (es) 2018-07-19
HRP20181558T1 (hr) 2018-11-30
PL3321276T3 (pl) 2022-01-17
GT201400055A (es) 2017-09-28
CN107266579A (zh) 2017-10-20
JP2018023370A (ja) 2018-02-15
EP2760475A1 (en) 2014-08-06
EP3321276A3 (en) 2018-06-20
CY1120928T1 (el) 2019-12-11
EA201490695A1 (ru) 2015-10-30
LT2760475T (lt) 2018-10-25
MA35437B1 (fr) 2014-09-01
HRP20211575T1 (hr) 2022-02-04
PT2760475T (pt) 2018-10-25
UY39119A (es) 2021-04-30
HK1251238A1 (en) 2019-01-25
UY34346A (es) 2013-04-30
US9266935B2 (en) 2016-02-23
ES2689762T3 (es) 2018-11-15
DK3321276T3 (da) 2021-10-25
CN103945871B (zh) 2017-04-26
AP2014007543A0 (en) 2014-03-31
RS62341B1 (sr) 2021-10-29

Similar Documents

Publication Publication Date Title
AR088044A1 (es) Proteinas de fusion para tratar trastornos metabolicos
CR20130234A (es) Métodos de tratamiento de trastornos asociados con el fgf21
CR20150149A (es) Proteínas de fusión para el tratamiento de un síndrome metabólico
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
CU20140035A7 (es) Proteínas de función dual para tratar trastornos metabólicos
CO7151525A2 (es) Proteínas del factor 21 de crecimiento del fibroblasto
PE20160847A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
PE20160877A1 (es) Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion
PE20160848A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
PE20181329A1 (es) Metodos y composiciones para el tratamiento del sindrome de hunter
CU20160082A7 (es) Un proceso para la preparación de una composición de proteínas pegiladas
AR087640A1 (es) Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma
CY1124859T1 (el) Ομοδιμερικο πεπτιδιο για τη θεραπεια του διαβητη και σχετικων νοσων
TH145764A (th) วิธีการสำหรับการบำบัดความผิดปกติที่เกี่ยวข้องกับ fgf21

Legal Events

Date Code Title Description
FG Grant, registration